Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Korro Bio, Inc. Common Stock

KRRO

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Last trade $12.29
Day change -$0.42 (-3.30%)
Day range $12.16 – $13.05
Volume 103,879
Market cap $174M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$174.45M
Price / earnings
—
Price / book
1.97×
Price / sales
135.03×
EV / sales
103.9×
EV / EBITDA
-1.84×

Profitability

Earnings per share
-$7.73
Return on assets
-71.65%
Return on equity
-120.09%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
7.3×
Quick ratio
7.3×
Cash ratio
2.69×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$63.87M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for KRRO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$1.29M$1.09M$1.46M$2.55M$2.27M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$1.29M$1.09M$1.46M$2.55M$2.27M
Selling, general and administrative$6.35M$6.52M$7.49M$6.19M$6.51M$7.29M$7.83M$8.35M
Research and development$12.1M$13.59M$12.95M$10.99M$13.82M$20.14M$19.74M$16.96M
Total operating expenses$18.46M$20.11M$20.44M$51.69M$20.33M$28.66M$27.57M$25.31M
Operating income-$18.46M-$20.11M-$20.44M-$50.4M-$19.24M-$27.2M-$25.02M-$23.04M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$17.29M-$18.81M-$19.53M-$49.41M-$18.06M-$25.77M-$23.39M-$21.1M
Income taxes$260K$108K$95K$636K$0$1K$0$103K
Net income-$17.55M-$18.92M-$19.63M-$50.04M-$18.06M-$25.77M-$23.39M-$21.2M
Net income attributable to common shareholders-$17.55M-$18.92M-$19.63M-$50.04M-$18.06M-$25.77M-$23.39M-$21.2M
EBITDA-$18.1M-$19.75M-$20.06M-$15.23M-$18.06M-$24.74M-$23.8M-$21.79M
Basic earnings per share-$0.98-$1.07-$1.69-$5.31-$1.92-$2.74-$2.49-$2.26
Diluted earnings per share-$0.98-$1.07-$1.69-$5.31-$1.92-$2.74-$2.49-$2.26

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Korro to Present at the 2026 Jefferies Global Healthcare Conference in London

Korro Bio, a clinical-stage biopharmaceutical company developing genetic medicines using its OPERA platform for RNA editing, announced that CEO Ram Aiyar will present at the Jefferies Global Healthcare Conference in London on November 19, 2026. The company is advancing its portfolio including KRRO-121 in Phase 1/2 trials and KRRO-111 for alpha-1 antitrypsin deficiency treatment.

Zacks Investment Research

MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?

MediWound (MDWD) shares rose 6.1% following strong commercial performance of its NexoBrid therapy for burn treatment, with record quarterly revenue and growing hospital adoption. The company expects quarterly losses of $0.66 per share but projects 40.4% revenue growth. However, unchanged earnings estimates suggest caution about sustained momentum.

Zacks Investment Research

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

Korro Bio (KRRO) shares jumped 29.7% following announcement of encouraging preclinical results for KRRO-111, an RNA-editing therapy for alpha-1 antitrypsin deficiency. The candidate showed strong activity in restoring functional protein while reducing harmful protein in the liver. However, earnings estimate revisions remain unchanged, which may limit sustained upward momentum. The stock carries a Zacks Rank #3 (Hold).

GlobeNewswire Inc.

Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Korro Bio announced that CEO Ram Aiyar will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The biopharmaceutical company is focused on developing RNA editing genetic medicines for rare and prevalent diseases. A live webcast will be available on their investor relations website.

GlobeNewswire Inc.

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Korro Bio, a clinical-stage biopharmaceutical company, announced that the FDA has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is currently being evaluated in a Phase 1/2a clinical study, and the company expects to report interim data in the second half of 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.